Abstract
Aromatase inhibitors (AIs) are a standard of care for the adjuvant treatment of hormone responsive early carcinoma of the breast as demonstrated in a number of large international phase III randomised trials. Arthralgia was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice. Although rates of up 35% have been reported in the randomised trials, the figure has been much higher in subsequent case series. There is concern that these symptoms are significant and may affect compliance and thus the overall efficacy of treatment. It is therefore extremely important that we evaluate this syndrome with a view to gaining more information regarding its clinical features and possible aetiological mechanism. The potential aetiological mechanisms and evidence for aromatase inhibitor-induced arthralgia (AIA) are reviewed in this article. Looking forward, it is now important that prospective clinical trials are well designed to evaluate this syndrome and potential therapeutic strategies to circumvent it. Radiological imaging and biochemical analyses may help our understanding of AIA and these are discussed.
Similar content being viewed by others
References
EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
Bonneterre J et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18(22):3748–3757
Mouridsen H et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21(11):2101–2109
Nabholtz JM et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22):3758–3767
Howell A et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62
Goss PE et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802
Coombes RC et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092
Coombes RC et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570
Jakesz R et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455–462
Thurlimann B et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757
Boccardo F et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(7): vii10–4
Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270–282
Njar VC, Brodie AM (1999) Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 58(2):233–255
Campos SM (2004) Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 9(2):126–136
di Salle E et al (1992) Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 43(1–3):137–143
Greendale GA, Lee NP, Arriola ER (1999) The menopause. Lancet 353(9152):571–580
Cecil RL, Archer BH (1925) Arthritis of the menopause. JAMA 84:75–79
Avis N et al (2004) Baillere’s clinical endocrinology and metabolism. In: Burger H (ed) The evolution of menopausal symptoms. Bailliere Tindall, London
Dugan SA et al (2006) Musculoskeletal pain and menopausal status. Clin J Pain 22(4):325–331
Xu J et al (2005) Natural history of menopause symptoms in primary care patients: a MetroNet study. J Am Board Fam Pract 18(5):374–382
Szoeke CE et al (2008) The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study. Climacteric 11(1):55–62
Huang C et al (1997) Factors associated with joint pain among postmenopausal women. Int J Obes Relat Metab Disord 21(5):349–354
Dowsett M, Lonning PE (1997) Anastrozole–a new generation in aromatase inhibition: clinical pharmacology. Oncology 54(Suppl 2):11–14
Nielsen RH et al (2008) Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin Exp Immunol 152(1):21–27
Cvoro A et al (2008) Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 180(1):630–636
Dawson-Basoa M, Gintzler AR (1997) Involvement of spinal cord delta opiate receptors in the antinociception of gestation and its hormonal simulation. Brain Res 757(1):37–42
Riley JL 3rd et al (1999) A meta-analytic review of pain perception across the menstrual cycle. Pain 81(3):225–235
Dietrich W et al (2006) Estrogen receptor-beta is the predominant estrogen receptor subtype in normal human synovia. J Soc Gynecol Investig 13(7):512–517
Coleman RE et al (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275–282
Richette P, Corvol M, Bardin T (2003) Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 70(4):257–262
Sniekers YH et al (2008) Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment—a systematic approach. Osteoarthr Cartil 16(5):533–541
Oestergaard S et al (2006) Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 54(8):2441–2451
Nevitt MC et al (2001) The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 44(4):811–818
Le Bail J et al (2001) Aromatase in synovial cells from postmenopausal women. Steroids 66(10):749–757
Sasano H et al (1997) Aromatase in human bone tissue. J Bone Miner Res 12(9):1416–1423
Toesca A et al (2008) Estrogen and progesterone receptors in carpal tunnel syndrome. Cell Biol Int 32(1):75–79
Morel B, Marotte H, Miossec P (2007) Will steroidal aromatase inhibitors induce rheumatoid arthritis? Ann Rheum Dis 66(4):557–558
Laroche M et al (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren’s syndrome. J Rheumatol 34(11):2259–2263
Henry NL et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372
Pfeilschifter J et al (2002) Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23(1):90–119
Mao JJ et al (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16):3631–3639
Sestak I et al (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866–872
Buzdar A (2006) Clinical features of joint symptoms observed in the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24(18S): 551
Buzdar A et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7(8):633–643
Fallowfield L et al (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22(21):4261–4271
Cella D et al (2006) Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100(3):273–284
Khanduri S, Dodwell DJ (2007) Aromatase inhibitors and musculoskeletal symptoms. Breast 17(1):76–79
Cuzick J et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143–1148
Fallowfield L (2008) There’s many a slip twixt cup and lip: adherence issues in cancer therapy. Nat Clin Pract Oncol 5(3):118–119
Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71(1–2):1–9
Fallowfield LJ et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917
Whelan TJ et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23(28):6931–6940
Felson DT (2008) Comparing the prevalence of rheumatic diseases in China with the rest of the world. Arthritis Res Ther 10(1):106
Crew KD et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883
Presant CA et al (2007) Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 7(10):775–778
Dent SF et al (2007) Adjuvant aromatse inhibitors in early breast cancer—toxicity and adherence. Important observations in clinical practice. In: San Antonio breast cancer symposium. San Antonio, Texas
Renshaw L et al (2007) Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. In: San Antonio breast caner symposium, p 2072
Morales L et al (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104(1):87–91
Morales L et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19):3147–3152
Alegre-Sancho JJ et al (2008) Trigger thumb in patients with breast cancer and hand pain associated with aromatase inhibitors. Ann Rheum Dis 67(Suppl II)
Dizdar O et al (2009) Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 27(30):4955–4960
Sestak I, Sapunar F, Cuzick J (2009) Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 27(30):4961–4965
Sestak I, Cuzick J (2007) Risk factors for joint symptoms in the ATAC trial. In: San Antonio breast caner symposium, p 2071
Singh S, Howell A, Cuzick J (2006) Vit D levels among patients with arthralgia: results from IBIS-II breast cancer prevention study. In: San Antonio breast caner symposium, p 1068
Azria D et al (2007) Letrozole induced arthralgia: results of a multicentric prospective trial exploring clinical parameters and plasma biomarkers. In: ASCO breast cancer symposium, p 228
Khan QJ et al (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119(1):111–118
Mao JJ et al (2009) Feasibility trial of electroacupuncture for aromatase inhibitor-related arthralgia in breast cancer survivors. Integr Cancer Ther 8(2):123–129
Crew KD et al (2009) Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 27(15s): 571
Basch E et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909
Hershman DL (2008) Getting a grip on aromatase inhibitor-associated arthralgias. J Clin Oncol 26(19):3120–3121
Allen KD et al (2007) Validity and factor structure of the AUSCAN Osteoarthritis Hand Index in a community-based sample. Osteoarthr Cartil 15(7):830–836
Sautner J et al (2004) Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands). Rheumatology 43(11):1409–1413
Sautner J et al (2009) A comparison of the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands and the Australian/Canadian Osteoarthritis Hand Index in Hand Osteoarthritis Patients. Int J Rheumatol 1–7
Harkonen R, Harju R, Alaranta H (1993) Accuracy of the Jamar dynamometer. J Hand Ther 6(4):259–262
Mathiowetz V et al (1984) Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am 9(2):222–226
Backhaus M et al (2001) Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 60(7):641–649
Wakefield RJ et al (2005) Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 32(12):2485–2487
Schmidt WA (2007) Technology insight: the role of color and power Doppler ultrasonography in rheumatology. Nat Clin Pract Rheumatol. 3(1): 35–42 (quiz 59)
Tan AL, Emery P (2008) Role of oestrogen in the development of joint symptoms? Lancet Oncol 9(9):817–818
Tan AL et al (2003) Imaging of the musculoskeletal system: magnetic resonance imaging, ultrasonography and computed tomography. Best Pract Res Clin Rheumatol 17(3):513–528
Haavardsholm EA et al (2007) Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. Ann Rheum Dis 66(9):1216–1220
Haavardsholm EA et al (2005) Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 52(12):3860–3867
Lester JE et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14(19):6336–6342
Brufsky A et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13(5):503–514
Ellis GK et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875–4882
Haugeberg G et al (2006) Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 65(6):736–740
Haugeberg G et al (2007) Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 66(11):1513–1517
Henry NL et al (2008) A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms. In: SABCS. San Antonio, Texas
Hunter DJ et al (2007) Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 9(5):R108
Williams FM, Spector TD (2008) Biomarkers in osteoarthritis. Arthritis Res Ther 10(1):101
Landewe R (2007) Predictive markers in rapidly progressing rheumatoid arthritis. J Rheumatol Suppl 80:8–15
Wild N et al (2008) Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers. Biomarkers 13(1):88–105
ClinicalTrials.gov. 2009 7th July 2009]; Available from: http://clinicaltrials.gov/ct2/results?term=breast+cancer+AND+arthralgia
Jakesz R et al (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99(24):1845–1853
Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3):223–234
Bianchi S et al. (2007) Ultrasound of the digital flexor system: normal and pathological findings. J Ultrasound 10:85–92
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Din, O.S., Dodwell, D., Wakefield, R.J. et al. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?. Breast Cancer Res Treat 120, 525–538 (2010). https://doi.org/10.1007/s10549-010-0757-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-010-0757-7